COLLINS FRANK E 4
4 · PharMerica CORP · Filed Dec 8, 2017
Insider Transaction Report
Form 4
COLLINS FRANK E
Director
Transactions
- Disposition to Issuer
Common Stock, $0.01 par value
2017-12-07$29.25/sh−60,262$1,762,664→ 0 total - Gift
Common Stock, $0.01 par value
2017-12-04−1,161→ 60,262 total
Footnotes (2)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent.
- [F2]Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share; (ii) the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration"); and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, multiplied by (y) the Merger Consideration.